Details for Patent: 12,514,899
Which drugs does patent 12,514,899 protect, and when does it expire?
Patent 12,514,899 protects KIMYRSA and ORBACTIV and is included in two NDAs.
This patent has twenty-seven patent family members in seventeen countries.
Summary for Patent: 12,514,899
| Title: | Methods of treatment using single doses of oritavancin |
| Abstract: | Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described. |
| Inventor(s): | Dario Lehoux, Thomas R. Parr, Gregory Moeck, Pierre Etienne |
| Assignee: | Melinta Therapeutics LLC |
| Application Number: | US13/763,799 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 12,514,899
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | 12,514,899 | ⤷ Start Trial | TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS DYSGALACTIAE WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT | ⤷ Start Trial | ||||
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 12,514,899 | ⤷ Start Trial | TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS DYSGALACTIAE WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,514,899
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2337575 | ⤷ Start Trial | 300834 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2337575 | ⤷ Start Trial | CA 2016 00044 | Denmark | ⤷ Start Trial |
| European Patent Office | 2337575 | ⤷ Start Trial | 41/2016 | Austria | ⤷ Start Trial |
| European Patent Office | 2337575 | ⤷ Start Trial | 122016000075 | Germany | ⤷ Start Trial |
| European Patent Office | 2337575 | ⤷ Start Trial | 1690041-7 | Sweden | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
